scholarly journals Comparison of cancer detection rates by transrectal prostate biopsy for prostate cancer using two different nomograms based on patient’s age and prostate volume

2019 ◽  
Vol Volume 11 ◽  
pp. 61-68
Author(s):  
Shunta Hori ◽  
Nobumichi Tanaka ◽  
Yasushi Nakai ◽  
Yosuke Morizawa ◽  
Yoshihiro Tatsumi ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Cancer Detection ◽  
Prostate Biopsy ◽  
Prostate Volume ◽  
Detection Rates ◽  
Transrectal Prostate Biopsy

Comparison of prostate cancer detection rates between the Vienna nomogram and the 10-core biopsy protocol

2019 ◽  
Vol 87 (3) ◽  
pp. 155-159
Author(s):  
Ersan Arda ◽  
Zafer Demir ◽  
Ilkan Yuksel ◽  
Mete Cek
Keyword(s):  
Prostate Cancer ◽  
Cancer Detection ◽  
Prostate Biopsy ◽  
Prostate Volume ◽  
Specific Antigen ◽  
Tissue Sampling ◽  
Exclusion Criteria ◽  
Detection Rates ◽  
Biopsy Protocol ◽  
Lower Urinary

Objective: To compare the Vienna nomogram and the 10-core prostate biopsy protocol regarding whether there is superiority in prostate cancer detection. Methods: Between January and December 2012, a total of 215 patients applying to our outpatient clinic with lower urinary tract symptoms were evaluated, prospectively. Patients with a prostate-specific antigen level of 2.5–10 ng/mL and/or suspicious digital rectal examination were included in the study. Exclusion criteria were determined as recent pelvic radiotherapy, lower urinary tract surgery, history of acute urinary retention, or indwelling urinary catheter. Biopsies were taken systematically with at least 10 cores considering prostate volume and patient age. According to Vienna nomogram, in patients requiring 6- or 8-core biopsies, tissue sampling was completed to 10 cores (our standard protocol), whereas in patients requiring more than 10 cores additional tissue sampling was performed. Results: After the determination of inclusion/exclusion criteria, 170 patients were enrolled in our study. The median (min–max) age, prostate-specific antigen value, and prostate volume were 65 (48–86) years, 7.6 ng/dL (2.5–10), and 55 cc (17–150), respectively. Prostate cancer was detected in 49 (28.8%) patients with transrectal ultrasound–guided prostate biopsy according to the Vienna nomogram. We found that our standard 10-core biopsy protocol would have diagnosed prostate cancer in 46 (27.1%) patients in the same study group showing no statistically significant difference (p > 0.005). Conclusion: The findings of this study suggest that considering cancer detection rates no statistically significant differences were found between both methods. Further prospective research in this aspect is needed to define the ultimate prostate biopsy protocol.

scholarly journals Cancer Detection Rates of Systematic and Targeted Prostate Biopsies after Biparametric MRI

2020 ◽  
Vol 2020 ◽  
pp. 1-6
Author(s):  
Maudy C. W. Gayet ◽  
Anouk A. M. A. van der Aa ◽  
Harrie P. Beerlage ◽  
Bart Ph Schrier ◽  
Maaike Gielens ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Cancer Detection ◽  
Prostate Biopsy ◽  
Detection Rates ◽  
Prostate Biopsies ◽  
Significant Difference ◽  
Significant Pathology ◽  
Study Population ◽  
Clinically Significant ◽  
Control Study

Objective. To compare prostate cancer detection rates (CDRs) and pathology results with targeted prostate biopsy (TB) and systematic prostate biopsy (SB) in biopsy-naive men. Methods. An in-patient control study of 82 men undergoing SB and subsequent TB in case of positive prostate MRI between 2015 and 2017 in the Jeroen Bosch Hospital, the Netherlands. Results. Prostate cancer (PCa) was detected in 54.9% with 70.7% agreement between TB and SB. Significant PCa (Gleason score ≥7) was detected in 24.4%. The CDR with TB and SB was 35.4% and 48.8%, respectively (p=0.052). The CDR of significant prostate cancer with TB and SB was both 20.7%. Clinically significant pathology upgrading occurred in 7.3% by adding TB to SB and 22.0% by adding SB to TB. Conclusions. There is no statistically significant difference between CDRs of SB and TB. Both SB and TB miss significant PCas. Moreover, pathology upgrading occurred more often by adding SB to TB than vice versa. This indicates that the omission of SB in this study population might not be justified.

scholarly journals 3D versus 2D Systematic Transrectal Ultrasound-Guided Prostate Biopsy: Higher Cancer Detection Rate in Clinical Practice

2013 ◽  
Vol 2013 ◽  
pp. 1-5 ◽  
Author(s):  
Alexandre Peltier ◽  
Fouad Aoun ◽  
Fouad El-Khoury ◽  
Eric Hawaux ◽  
Ksenija Limani ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Cancer Detection ◽  
Prostate Biopsy ◽  
Detection Rate ◽  
Transrectal Ultrasound ◽  
Daily Practice ◽  
Cancer Detection Rate ◽  
Prior History ◽  
Detection Rates ◽  
Significant Difference

Objectives. To compare prostate cancer detection rates of extended 2D versus 3D biopsies and to further assess the clinical impact of this method in day-to-day practice.Methods. We analyzed the data of a cohort of 220 consecutive patients with no prior history of prostate cancer who underwent an initial prostate biopsy in daily practice due to an abnormal PSA and/or DRE using, respectively, the classical 2D and the new 3D systems. All the biopsies were done by a single experienced operator using the same standardized protocol.Results. There was no significant difference in terms of age, total PSA, or prostate volume between the two groups. However, cancer detection rate was significantly higher using the 3D versus the 2D system, 50% versus 34% (P<0.05). There was no statistically significant difference while comparing the 2 groups in term of nonsignificant cancer detection.Conclusion. There is reasonable evidence demonstrating the superiority of the 3D-guided biopsies in detecting prostate cancers that would have been missed using the 2D extended protocol.

scholarly journals The urologist’s learning curve of “in-bore” magnetic resonance-guided prostate biopsy

BMC Urology ◽  
2021 ◽  
Vol 21 (1) ◽  
Author(s):  
Barak Rosenzweig ◽  
Tomer Drori ◽  
Orit Raz ◽  
Gil Goldinger ◽  
Gadi Shlomai ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Learning Curve ◽  
Cancer Detection ◽  
Prostate Biopsy ◽  
Detection Rate ◽  
Medical Center ◽  
Detection Rates ◽  
Targeted Sampling ◽  
The Mean ◽  
Clinically Significant

Abstract Background The combination of multi-parametric MRI to locate and define suspected lesions together with their being targeted by an MRI-guided prostate biopsy has succeeded in increasing the detection rate of clinically significant disease and lowering the detection rate of non-significant prostate cancer. In this work we investigate the urologist’s learning curve of in-bore MRI-guided prostate biopsy which is considered to be a superior biopsy technique. Materials and methods Following Helsinki approval by The Chaim Sheba Medical Center ethics committee in accordance with The Sheba Medical Center institutional guidelines (5366-28-SMC) we retrospectively reviewed 110 IB-MRGpBs performed from 6/2016 to 1/2019 in a single tertiary center. All patients had a prostate multi-parametric MRI finding of at least 1 target lesion (prostate imaging reporting and data system [PI-RADS] score ≥ 3). We analyzed biopsy duration and clinically significant prostate cancer detection of targeted sampling in 2 groups of 55 patients each, once by a urologist highly trained in IB-MRGpBs and again by a urologist untrained in IB-MRGpBs. These two parameters were compared according to operating urologist and chronologic order. Results The patients’ median age was 68 years (interquartile range 62–72). The mean prostate-specific antigen level and prostate size were 8.6 ± 9.1 ng/d and 53 ± 27 cc, respectively. The mean number of target lesions was 1.47 ± 0.6. Baseline parameters did not differ significantly between the 2 urologists’ cohorts. Overall detection rates of clinically significant prostate cancer were 19%, 55%, and 69% for PI-RADS 3, 4 and 5, respectively. Clinically significant cancer detection rates did not differ significantly along the timeline or between the 2 urologists. The average duration of IB-MRGpB targeted sampling was 28 ± 15.8 min, correlating with the number of target lesions (p < 0.0001), and independent of the urologist’s expertise. Eighteen cases defined the cutoff for the procedure duration learning curve (p < 0.05). Conclusions Our data suggest a very short learning curve for IB-MRGpB-targeted sampling duration, and that clinically significant cancer detection rates are not influenced by the learning curve of this technique.

scholarly journals The 20-core prostate biopsy as an initial strategy: impact on the detection of prostatic cancer

2013 ◽  
Vol 4 (2) ◽  
pp. 100 ◽  
Author(s):  
Mohamed Amine Jradi ◽  
Mohamed Dridi ◽  
Mourad Teyeb ◽  
Mokhtar Ould Sidi Mohamed ◽  
Ramzi Khiary ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Cancer Detection ◽  
Prostate Biopsy ◽  
Detection Rate ◽  
Prostate Volume ◽  
Cancer Detection Rate ◽  
Dépistage Du Cancer ◽  
Biopsy Protocol ◽  
Group 2 ◽  
Group 1

Introduction: To increase the detection rate of prostate cancer inrecent years, we examined the increase in the number of corestaken at initial prostate biopsy. We hypothesized that an increasingnumber of cores may undermine the accuracy of models predictingthe presence of prostate cancer at initial biopsy in patientssubmitted to 20-core initial biopsy.Methods: A total of 232 consecutive patients with prostatespecificantigen (PSA) between 4 and 20 ng/mL and/or abnormaldigital rectal examination (DRE) underwent 12-core prostate biopsyprotocol (group 1) or 20-core prostate biopsy protocol (group 2).The patients were divided into subgroups according to the resultsof their serum PSA and prostate volume. We evaluated the cancerdetection rate overall and in each subgroup. Clinical datawere analyzed using chi-square analysis and the unpaired t-testor 1-way ANOVA with significance considered at 0.05.Results: The 2 groups of patients were not significantly different withregard to parameters (age, abnormal DRE and serum PSA), althoughmedian prostate volume in group 1 (57.76 ± 26.94 cc) were slightergreater than in group 2. Cancer detection rate for patients submittedto 20 prostate biopsy was higher than patients submitted to 12prostate biopsy (35.2% vs. 25%, p = 0.095). Breakdown to PSAlevel showed a benefit to 20 prostate biopsy for PSA <6 ng/mL (37.1%vs. 12.9%, p = 0.005). Stratifying results by prostate volume, wefound that the improvement of cancer detection rate with 20 prostatebiopsy was significant in patients with a prostate volume greaterthan 60 cc (55% in 20 prostate biopsy vs. 11.3% p < 0.05). Morbidityrates were identical in groups 1 and 2 with no statistically significantdifference. There appeared to be no greater risk of infectionand bleeding with 20 prostate biopsy protocol.Conclusion: The 20-core biopsy protocol was more efficient thanthe 12-core biopsy protocol, especially in patients with prostatespecific antigen <6 ng/mL and prostate volume greater than 60 cc.Introduction : Pour augmenter le taux de détection du cancer de laprostate dans un avenir rapproché, nous avons examiné l’incidenced’une hausse du nombre de carottes prélevées lors de la biopsieprostatique initiale. Notre hypothèse était qu’en raison du nombreaccru de prélèvements, la biopsie à 20 carottes pouvait réduirel’exactitude des modèles de dépistage du cancer de la prostate à labiopsie initiale.Méthodologie : Au total, 232 patients consécutifs avec des tauxd’antigène prostatique spécifique (APS) situés entre 4 et 20 ng/mLet/ou des anomalies au toucher rectal ont subi une biopsie prostatiqueà 12 (groupe 1) ou à 20 carottes (groupe 2). Les patients ontété répartis en sous-groupes en fonction de leurs taux sériques d’APSet de leur volume prostatique. Nous avons évalué le taux de dépistagedu cancer de façon globale et par sous-groupes. Les données cli -niques ont été analysées par la méthode du chi carré et du test tpour échantillons non appariés ou par analyse unilatérale de lavariance (ANOVA), avec un seuil de signification de 0,05.Résultats : On n’a noté aucune différence significative entre lesdeux groupes quant aux paramètres (âge, anomalie au toucher rectalet taux sériques d’APS), malgré que le volume prostatique médianait été légèrement supérieur dans le groupe 1 (57,76 ± 26,94 mL)par rapport au groupe 2. Le taux de dépistage du cancer avec labiopsie prostatique à 20 carottes était plus élevé que le taux obtenuavec la biopsie à 12 carottes (35,2 % vs 25 %, p = 0,095). La répartitiondes patients en fonction des taux d’APS a fait ressortir unavantage pour la biopsie à 20 carottes lorsque les taux d’APS étaientinférieurs à 6 ng/mL (37,1 % vs 12,9 %, p = 0,005). La stratificationdes données selon le volume de la prostate a montré que lahausse des taux de dépistage du cancer associée à la biopsie prostatiqueà 20 carottes était significative lorsque le volume prostatiquedépassait 60 mL (55 % pour la biopsie à 20 carottes vs 11,3 %,p < 0,05). Les taux de morbidité étaient semblables dans les deuxgroupes, la différence n’étant pas significative sur le plan statistique.La biopsie prostatique à 20 carottes ne semblait pas associéeà un risque plus élevé d’infection et d’hémorragie.Conclusion : La biopsie à 20 carottes était plus efficace que la biopsieà 12 carottes, surtout chez les patients dont le taux d’APS était

Sign in / Sign up

Export Citation Format

Share Document